Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Neurofilament light chain level is a weak risk factor for the development of MS

  • Arrambide, Georgina|||0000-0002-2657-5510
  • Espejo, Carmen|||0000-0001-9949-5901
  • Eixarch, Herena|||0000-0001-7525-9533
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Picón, Carmen
  • Kuhle, Jens|||0000-0002-6963-8892
  • Disanto, Giulio
  • Kappos, Ludwig|||0000-0003-4175-5509
  • Sastre-Garriga, Jaume|||0000-0002-1589-2254
  • Pareto, Deborah|||0000-0001-7356-3769
  • Simon, Eva
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Río, Jordi|||0000-0003-4546-7627
  • Nos, Carlos|||0000-0002-3830-4910
  • Tur, Carmen|||0000-0003-1849-3184
  • Castilló, Joaquín|||0000-0002-8951-6315
  • Vidal-Jordana, Angela|||0000-0002-7270-5507
  • Galan, Ingrid|||0000-0001-5774-4260
  • Arévalo, María Jesús|||0000-0003-0626-5555
  • Auger, Cristina|||0000-0001-9846-4767
  • Rovira, Alex|||0000-0002-2132-6750
  • Montalban, Xavier|||0000-0002-0098-9918
  • Tintoré, Mar|||0000-0001-9999-5359
To determine the prognostic value of selected biomarkers in clinically isolated syndromes (CIS) for conversion to multiple sclerosis (MS) and disability accrual. Data were acquired from 2 CIS cohorts. The screening phase evaluated patients developing clinically definite MS (CIS-CDMS) and patients who remained as CIS during a 2-year minimum follow-up (CIS-CIS). We determined levels of neurofascin, semaphorin 3A, fetuin A, glial fibrillary acidic protein, and neurofilament light (NfL) and heavy chains in CSF (estimated mean [95% confidence interval; CI]). We evaluated associations between biomarker levels, conversion, disability, and magnetic resonance parameters. In the replication phase, we determined NfL levels (n = 155) using a 900 ng/L cutoff. Primary endpoints in uni- and multivariate analyses were CDMS and 2010 McDonald MS. The only biomarker showing significant differences in the screening was NfL (CIS-CDMS 1,553.1 [1,208.7-1,897.5] ng/L and CIS-CIS 499.0 [168.8-829.2] ng/L, p < 0.0001). The strongest associations were with brain parenchymal fraction change (r = -0.892) and percentage brain volume change (r = -0.842) at 5 years. NfL did not correlate with disability. In the replication phase, more NfL-positive patients, according to the cutoff, evolved to MS. Every 100-ng/L increase in NfL predicted CDMS (hazard ratio [HR] = 1.009, 95% CI 1.005-1.014) and McDonald MS (HR = 1.009, 95% CI 1.005-1.013), remaining significant for CDMS in the multivariate analysis (adjusted HR = 1.005, 95% CI 1.000-1.011). This risk was lower than the presence of oligoclonal bands or T2 lesions. NfL is a weak independent risk factor for MS. Its role as an axonal damage biomarker may be more relevant as suggested by its association with medium-term brain volume changes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor

  • Miralles, Marta
  • Eixarch, Herena|||0000-0001-7525-9533
  • Tejero Ambrosio, Marcos
  • Costa, Carme|||0000-0001-9577-3839
  • Hirota, Keiji
  • Castaño, Ángel Raúl|||0000-0003-2107-8862
  • Puig Ferrer, Meritxell
  • Stockinger, Gitta
  • Montalban, Xavier|||0000-0002-0098-9918
  • Bosch i Merino, Assumpció|||0000-0002-7205-2796
  • Espejo, Carmen|||0000-0001-9949-5901
  • Chillón Rodríguez, Miguel|||0000-0003-0840-2111
The role of the T helper (Th)17 pathway has been clearly demonstrated in the onset and progression of autoimmune diseases, where interleukin (IL)-23 is a key molecule in maintaining the response mediated by Th17 cells. As a consequence, recent strategies based on blocking the interaction between IL-23 and its receptor (IL-23R), for example the anti-p19 antibody tildrakizumab, have been developed to regulate the Th17 pathway from the initial stages of the disease. Here, a soluble (s)IL-23R cDNA was cloned in expression plasmids and viral vectors. The clinical efficacy of sIL-23R was evaluated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis mice intravenously injected with a single dose of adeno-associated virus AAV8- sIL-23R vectors. Cytokine secretion was determined by multiplexassay, while histopathological analysis of the central nervous system was performed to study demyelination, inflammatory infiltration, and microglia and astroglia activation. We observed that administration of adeno-associated vector 8 encoding sIL-23R was associated with a significant disease improvement,including delay in the onset of the clinical signs; slower progress of the disease;interference with IL-23- mediated signal transducer and activator of transcription response by inhibiting of signal transducer and activator of transcription 3 phosphorylation; reduced demyelination and infiltration in the central nervous system; and lower astrocyte and microglia activation. Our results suggest that the use of vectors carrying sIL-23R to block the IL-23/IL-23R interaction may be a new therapeutic strategy for the treatment of multiple sclerosis., The online version of this article (doi:10.1007/s13311-017-0545-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus

  • Carrillo-Salinas, Francisco J.|||0000-0002-7936-5859
  • Mestre, Leyre|||0000-0001-6970-2316
  • Mecha, Miriam
  • Feliú, Ana|||0000-0002-1157-1525
  • del Campo, Rosa|||0000-0003-1147-7923
  • Villarrubia, Noelia
  • Espejo, Carmen|||0000-0001-9949-5901
  • Montalban, Xavier|||0000-0002-0098-9918
  • Alvarez-Cermeño, José C.|||0000-0002-1345-2837
  • Villar, L. M.
  • Guaza, Carmen|||0000-0003-3240-9807
Recent studies have begun to point out the contribution of microbiota to multiple sclerosis (MS) pathogenesis. Theiler's murine encephalomyelitis virus induced demyelinating disease (TMEV-IDD) is a model of progressive MS. Here, we first analyze the effect of intracerebral infection with TMEV on commensal microbiota and secondly, whether the early microbiota depletion influences the immune responses to TMEV on the acute phase (14 dpi) and its impact on the chronic phase (85 dpi). The intracranial inoculation of TMEV was associated with a moderate dysbiosis. The oral administration of antibiotics (ABX) of broad spectrum modified neuroimmune responses to TMEV dampening brain CD4 + and CD8 + T infiltration during the acute phase. The expression of cytokines, chemokines and VP2 capsid protein was enhanced and accompanied by clusters of activated microglia disseminated throughout the brain. Furthermore, ABX treated mice displayed lower levels of CD4 + and CD8 + T cells in cervical and mesenteric lymph nodes. Increased mortality to TMEV was observed after ABX cessation at day 28pi. On the chronic phase, mice that survived after ABX withdrawal and recovered microbiota diversity showed subtle changes in brain cell infiltrates, microglia and gene expression of cytokines. Accordingly, the surviving mice of the group ABX-TMEV displayed similar disease severity than TMEV mice.